Browsing Tag
Astellas Pharma
22 posts
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.
March 16, 2023
Aurobindo Pharma announces FDA final approval for Amphotericin B Liposome for Injection
Aurobindo Pharma said that its fully-owned subsidiary — Eugia Pharma Specialities has secured final approval for Amphotericin B…
November 18, 2022
Astellas Pharma to acquire stake in biotech company Taysha GeneTherapies
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through…
October 26, 2022
Astellas hit by fatal event in ASPIRO clinical trial of AT132 in XLMTM
Astellas Pharma said that a participant in the ASPIRO clinical trial of AT132, who had developed a serious adverse event…
September 14, 2021
Japan approves Roxadustat for non-dialysis anemia in chronic kidney disease
Astellas Pharma and FibroGen have received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the…
November 28, 2020
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and…
February 20, 2020
Astellas Pharma acquires US biotech company Xyphos Biosciences
Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in…
December 28, 2019
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and…
December 19, 2019
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes…
December 8, 2019
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma…
November 2, 2019